MELVILLE, N.Y.--(BUSINESS WIRE)--Sept. 21, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has begun a Phase III clinical trial of Tarceva(R) (erlotinib) as a targeted adjuvant therapy in patients who have undergone surgery for non-small cell lung cancer (NSCLC) with EGFR-positive tumors. An oral, once-daily medication, Tarceva is currently indicated for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one chemotherapy regimen, and in combination with gemcitabine chemotherapy for the first-line treatment of locally advanced unresectable or metastatic pancreatic cancer. OSI is developing and commercializing Tarceva in collaboration with Genentech, Inc. and Roche.
